Across TCGA pan-cancer cohorts, ATP6V0A2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP6V0A2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP6V0A2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATP6V0A2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where ATP6V0A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.837	0.262	.027	4	view →
CCRCC	DFS	Median	III,IV	0.915	0.399	.040	3	view →
GBM	OS	Median	All	0.424	0.645	.028	2	view →
HNSC	OS	Quartile	II,III,IV	0.944	0.828	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ATP6V0A2 tumor-vs-normal RNA expression · all ATP6V0A2 data types